South San Francisco, CA October 4, 2018 Press Release FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only…
Tag: hemophilia
Genentech’s HEMLIBRA® Offers Promise to Hemophilia Patients
South San Francisco, CA August 30, 2018 Press Release Positive Phase III Results for Genentech’s HEMLIBRA® (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine — HEMLIBRA prophylaxis significantly reduced bleeds compared to no…
Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
South San Francisco, CA November 29, 2017 Genentech Press Release HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of HEMLIBRA prophylaxis compared to prior factor VIII prophylaxis SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00…
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
South San Francisco, CA November 16, 2017 Genentech Press Release First new medicine in nearly 20 years to treat people with hemophilia A with inhibitors HEMLIBRA substantially reduced bleeds in adults and children Only medicine that can be…
FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors
South San Francisco, CA August 24, 2017 Genentech Press Release Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children — SOUTH SAN FRANCISCO,…
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
South San Francisco, CA July 10, 2017 Genentech Press Release Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87 percent…
Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
South San Francisco, CA June 27, 2017 Press Release Genentech — Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies — — Data from HAVEN 1 in adults and adolescents and interim data from HAVEN…